GEFITINIB

作品数：142被引量：431H指数：10
导出分析报告
相关领域：医药卫生更多>>
相关作者：李龙芸马胜林吴一龙张晓彤张为民更多>>
相关机构：大连医科大学广东省人民医院广州军区广州总医院浙江省肿瘤医院更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金国家高技术研究发展计划上海市科学技术委员会资助项目更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Efficacy and safety of lenvatinib plus gefitinib in lenvatinibresistant hepatocellular carcinomas: a prospective, single-arm exploratory trial
《Signal Transduction and Targeted Therapy》2025年第1期314-320,共7页Yaoping Shi Dan Cui Lei Xia Donghua Shi Guangxin Jin Siying Wang Yan Lin Xiaoyin Tang Jiachang Chi Tao Wang Meng Li Zicheng Lv Jiaojiao Zheng Qi Jia Wu Yang Zhen Sun Fan Yang Hao Feng Shengxian Yuan Weiping Zhou Wenxin Qin Rene Bernards Haojie Jin Bo Zhai 
supported by the National Natural Science Foundation(Nos.82222047,82073039,82330095,81502672,and 82070619);the Program of Shanghai Academic/Technology Research Leader(No.22XD1423100);the National Key Research and Development Program of China(2022YFC2804300);Shanghai Municipal Commission of Health and Family Planning(2022XD057);the Shanghai Committee of Science and Technology(23ZR1439000 and 22S11900500).
Lenvatinib,a multi-kinase inhibitor,has been approved asfirst-line treatment for advanced hepatocellular carcinoma(HCC),but its efficacy is limited.We have shown previously that lenvatinib and epidermal growth factor ...
关键词：GEFITINIB DIARRHEA treatment 
Retraction:Downregulation of microRNA-135 promotes sensitivity of non-small cell lung cancer to gefitinib by targeting TRIM16
《Oncology Research》2024年第11期1813-1813,共1页Oncology Research Editorial Office 
Following the publication,concerns have been raised about a number of figures in this article.The western blots in this article were presented with atypical,unusually shaped and possibly anomalous protein bands in man...
关键词：raised concerned SHAPED 
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated,EGFR-mutated,advanced non-small cell lung cancer:data froma randomized phase III trial(AENEAS)
《Cancer Communications》2024年第9期1005-1017,共13页Shun Lu Xiaorong Dong Hong Jian Jianhua Chen Gongyan Chen Yuping Sun Yinghua Ji ZipingWang Jianhua Shi Junguo Lu Shaoshui Chen Dongqing Lv Guojun Zhang Chunling Liu Juan Li Xinmin Yu Zhong Lin Zhuang Yu ZhehaiWang Jiuwei Cui Xingxiang Xu Jian Fang Jifeng Feng Zhi Xu RuiMa Jie Hu Nong Yang Xiangdong Zhou XiaohongWu Chengping Hu Zhihong Zhang You Lu Yanping Hu Liyan Jiang Qiming wang Renhua Guo Jianying Zhou Baolan Li Chunhong Hu Wancheng Tong Helong Zhang LinMa Yuan Chen Zhijun Jie Yu Yao Longzhen Zhang JieWeng Weidong Li Jianping Xiong Xianwei Ye Jianchun Duan Haihua Yang Meili Sun HongyingWei JiaweiWei Zheyu Zhang QiongWu 
Hansoh Pharmaceutical Group Co.Ltd;National Natural Science Foundation of China,Grant/Award Numbers:82030045,82241227;National Multi-disciplinary Treatment Project for Major Diseases,Grant/Award Number:2020NMDTP;Collaborative Innovation Center for Clinical and Translational Science by Ministry of Education&Shanghai,Grant/Award Numbers:CCTS-202204,CCTS-202304;Shanghai Chest Hospital Basic Research Project,Grant/Award Number:2023YNKT-1;Pujiang Program,Grant/Award Number:22PJ1420700。
Background:The initial randomized,double-blinded,actively controlled,phase III ANEAS study(NCT03849768)demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first-line therapy in epidermal g...
关键词：aumolertinib brain metastasis non-small cell lung cancer third-generation EGFR-TKI 
Gefitinib(an EGFR tyrosine kinase inhibitor)plus anlotinib(an multikinase inhibitor)for untreated,EGFR-mutated,advanced non-small cell lung cancer(FL-ALTER):a multicenter phase III trial
《Signal Transduction and Targeted Therapy》2024年第9期4091-4102,共12页Hua-Qiang Zhou Ya-Xiong Zhang Gang Chen Qi-Tao Yu Hua Zhang Guo-Wu Wu Di Wu Ying-Cheng Lin Jun-Fei Zhu Jian-Hua Chen Xiao-Hua Hu Bin Lan Ze-Qiang Zhou Hai-Feng Lin Zi-Bing Wang Xiao-Lin Lei Suo-Ming Pan Li-Ming Chen Jian Zhang Tian-Dong Kong Ji-Cheng Yao Xin Zheng Feng Li Li Zhang Wen-Feng Fang 
funded by the Chinese National Natural Science Foundation Project(Grant No.82173101,82373262,82241232,82272789,82102864);Guangzhou Basic and Applied Basic Research Foundation(2024A04J4082);partly funded by the 308 Clinical Research Foundation of Sun Yat-sen University Cancer Center.
Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor(EGFR)signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy.In this phase 3 study(Clin...
关键词：cancer lung treatment 
呼吸系统肿瘤用药——2023版新型抗肿瘤药物临床应用指导原则(一)
《中国合理用药探索》2024年第3期34-38,共5页中华人民共和国国家卫生健康委员会 
吉非替尼(gefitinib)制剂:片剂;规格:250mg;适应症:表皮生长因子受体(epidermal growth factor receptor,EGFR)基因具有敏感突变的局部晚期或转移性非小细胞肺癌(non-small cell lung cancer,NSCLC)患者。
关键词：吉非替尼 表皮生长因子受体 药物临床应用 呼吸系统肿瘤 转移性非小细胞肺癌 抗肿瘤 GEFITINIB 局部晚期 
Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells被引量：1
《Chinese Chemical Letters》2024年第2期436-440,共5页Guizhen Zhu Yaoyao Zhao Wenmei Zhang Yuanyuan Wu Yuanxing Liu Guangsheng Guo Xiayan Wang Zhihong Liu 
supported by the Beijing Outstanding Young Scientist Program(No.BJJWZYJH01201910005017);the National Natural Science Foundation of China(Nos.22127805 and 22206008).
Patients with epidermal growth factor receptor(EGFR)wild-type non-small cell lung cancer(NSCLC)often show primary resistance to gefitinib therapy.It is thus necessary to study the metabolism of gefitinib in NSCLC cell...
关键词：Single-cell mass spectrometry Drug metabolism Non-small cell lung cancer GEFITINIB Primary resistance 
Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy:A secondary analysis of a phase 2 randomized clinical trial被引量：1
《Chinese Medical Journal Pulmonary and Critical Care Medicine》2023年第2期119-124,共6页Rui Han Jianghua Li Yubo Wang Tingting He Jie Zheng Yong He 
This work was supported by the National Natural Science Foundation of China(NSFC)(Nos.81972189,82172623,81802293,and 81902343);Chongqing Science and Technology Commission(No.cstc2021jcyj-msxmX0014).
Background:The synergistic association between metformin and epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitors(TKIs)has been confirmed in in vitro studies.It is still controversial which patients can b...
关键词：Non-small cell lung cancer METFORMIN Epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) Body mass index GEFITINIB 
SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16被引量：5
《Acta Pharmacologica Sinica》2023年第4期853-864,共12页Yuan Liu Wei-yao Kong Cui-fu Yu Zhen-long Shao Qiu-cheng Lei Yuan-fei Deng Geng-xi Cai Xue-fen Zhuang Wen-shuang Sun Shi-gang Wu Rong Wang Xiang Chen Guo-xing Chen Hong-biao Huang Yu-ning Liao 
supported by National Natural ScienceFoundation of China(82002481,82072810);the open researchfunds fromthe Sixth Affliated Hospitalof Guangzhou Medical University,Q,ingyuan People's Hospital(202011-304,202011-204);the Science and Technology Program of Guangzhou(202102020931);Natural Science Foundation Research Team of Guangdong Province(2018B030312001);Cultivation Program of National Natural Science Foundation for Distinguished Young Scholars of Guangzhou Medical University(JP2022002);Discipline Construction Funds of GuangzhouMedicalUniversity(JCXKJS2021C04,JCXKJS2021D03,and JCXKJS2021D06);Special Fund of Foshan Summit Plan(2020G010)and Guangzhou Key Medical Discipline Construction Project Fund.
Hepatocellular carcinoma(HCC)remains challenging due to the lack of efficient therapy.Promoting degradation of certain cancer drivers has become an innovative therapy.The nuclear transcription factor sine oculis homeo...
关键词：SNS-023 ML323 SORAFENIB GEFITINIB MK2206 
Gefitinib improves severe bronchorrhea and prolongs the survival of a patient with lung invasive mucinous adenocarcinoma:A case report
《World Journal of Clinical Cases》2023年第2期441-448,共8页Guo-Chun Ou Wen Luo Wei-Shan Zhang Shu-Hong Wang Jie Zhao Hong-Mei Zhao Rong Qiu 
Supported by the Science and Technology Research Project of Sichuan Provincial Administration of Traditional Chinese Medicine,No.2021MS164;Scientific research project of Sichuan Medical Association,No.S21012。
BACKGROUND Lung invasive mucinous adenocarcinoma(LIMA),formerly referred to as mucinous bronchioloalveolar carcinoma,is a rare disease that usually presents as bilateral lung infiltration,is unsuitable for surgery and...
关键词：GEFITINIB Epidermal growth factor receptor Lung cancer Bronchorrhea Lung invasive mucinous adenocarcinoma Case report 
Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer被引量：3
《Acta Pharmacologica Sinica》2023年第1期244-254,共11页Zi-tong Zhao Jue Wang Lei Fang Xin-di Qian Ying Cai Hai-qiang Cao Guan-ru Wang Mei-lin He Yan-yan Jiang Dang-ge Wang Ya-ping Li 
Financial support from the National Natural Science Foundation of China (81903548,32170935,32070927,81690265,31930066 and 82172615);the Youth Innovation Promotion Association of CAS (2019283);the Shanghai Sailing Program (19YF1457300);Shandong Provincial Natural Science Foundation (ZR2019PH013)are gratefully acknowledged.
The combination of vascular endothelial growth factor(VEGF)inhibitors and tyrosine kinase inhibitors(TKIs)is newly available for molecular targeted therapy against non-small cell lung cancer(NSCLC)in clinic.However,th...
关键词：NANOPARTICLES molecular targeted therapy non-small cell lung cancer dual-responsive controlled release 
全选清除导出
共15页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部